The European Cardiovascular Health Data and AI Network, known as CHAIN, has been launched with €20 million in funding from the EU4Health Programme and is coordinated by the European Society of Cardiology (ESC). The 36-month project brings together a consortium of 53 partners from 20 European countries, spanning universities and research centres, hospitals and clinical networks, technology companies, national ministries of health and patient organisations. Its central ambition is to build a federated ecosystem for the safe, effective and scalable adoption of AI in cardiovascular care, aligned with the European Health Data Space, the EU’s ambitious framework for cross-border health data sharing.

The problem CHAIN seeks to solve is well documented. AI models capable of detecting heart disease earlier, stratifying patient risk more accurately and supporting clinical decisions have proliferated in the scientific literature, yet their uptake in routine care remains patchy and inconsistent. Standardised validation mechanisms are largely lacking, meaning hospitals and health authorities often have no reliable way of knowing which algorithms perform as advertised, for which patient populations, and under which clinical conditions. The result is a landscape in which promising tools stall at the pilot stage while unvetted ones occasionally reach clinics without adequate scrutiny.

CHAIN’s technical answer to this challenge rests on two pillars: a federated data infrastructure and a system of validation credentials. Rather than centralising sensitive patient records, the project will securely connect hospitals, health data hubs and disease registries across Europe in a federated architecture, allowing AI solutions to be tested, validated and deployed at scale while data remain within their originating institutions. This approach, which aligns with the privacy-preserving principles underpinning the European Health Data Space, enables algorithms to be evaluated on diverse, real-world populations drawn from multiple healthcare systems, a critical step for detecting the biases and performance gaps that often emerge when models trained in one setting are applied in another.

The second pillar is a European repository of validated AI solutions, each accompanied by what the project calls an ‘AI passport’. These passports will document a model’s performance, safety and suitability for clinical use, giving healthcare authorities, hospital administrators and practicing clinicians clear, standardised evidence on which solutions work, for whom and in which settings. In an era when clinicians and patients alike are wary of opaque algorithmic tools, the passports are designed to function as a trusted seal of approval, helping decision-makers distinguish genuinely useful innovations from overhyped ones. Professor Folkert Asselbergs of Amsterdam University Medical Centre, CHAIN’s scientific coordinator and chair of the ESC AI Gateway, emphasised that in an era of misinformation, patients and healthcare professionals are looking to medical societies to provide a framework for implementing trusted solutions that add real value beyond what is currently available.

To prove the framework works in practice, CHAIN will implement six real-world use cases across 13 countries, deliberately chosen to cover the full continuum of cardiovascular care. The use cases span risk stratification, early disease detection, clinical decision support and the management of complex cardiovascular conditions, ensuring that the validation and deployment mechanisms are tested across different healthcare settings, from large academic centres to smaller regional hospitals. This breadth matters: an AI tool that performs well in a well-resourced Dutch university hospital may fail in a rural clinic in eastern Europe, and the project’s multi-country design is intended to surface such disparities before tools are scaled.

The initiative does not start from scratch. CHAIN builds on the ESC’s EuroHeart registry network, which already unifies 18 ESC member countries with standardised data on cardiovascular care and outcomes, providing tools that help countries monitor results, compare practices and drive sustainable improvements. It will also seek synergies with a constellation of existing EU projects, including EUCAIM, COMPASS AI, AI4HF, DataTools4Heart, EHDEN, JACARDI, TEHDAS2 and Xt-EHR, an effort to maximise complementarities and avoid duplicating infrastructure that Europe has already invested in. The project is explicitly positioned as a key implementation vehicle for the EU Safe Hearts Plan, in particular its flagship initiative on innovation and integration of AI and digital technologies in cardiovascular healthcare.

Timing is a central theme of the launch. CHAIN arrives just as the European Health Data Space, the EU’s landmark AI Act, and an evolving regulatory framework for medical products, spanning pharmaceutical, medical device and in vitro diagnostic legislation, are reshaping how AI is developed, evaluated and deployed across European healthcare. Navigating this regulatory landscape is one of the project’s implicit challenges: any AI tool validated through CHAIN will need to satisfy not only clinical evidence standards but also the transparency, safety and human-oversight requirements that the AI Act imposes on high-risk medical applications. By building governance, evaluation and scale-up mechanisms into its core design, the consortium hopes to create a template that regulators, industry and health systems can adopt more widely.

The political weight behind the project is considerable. Olivér Várhelyi, the EU Commissioner for Health and Animal Welfare, framed the challenge bluntly, saying the question is no longer simply what AI can do, but how to make it work safely and effectively for patients and health professionals in everyday healthcare, and that this is where CHAIN can make a real difference. Professor Cecilia Linde, President of the ESC and a cardiologist at the Karolinska Institute in Sweden, struck a similar note, arguing that the need to act is critical given that one in three deaths in Europe is caused by cardiovascular disease, and describing CHAIN as an effort to turn the promise of AI into better cardiovascular health for everyone by helping trusted innovations reach patients safely and equitably.

Over the next three years, the consortium hopes to deliver a strategic roadmap for scaling AI adoption in cardiology across Europe, one that Professor Asselbergs says will benefit research and industry through shared infrastructure and standards, while validated decision-support tools help reduce the burden on overstretched healthcare systems. The ultimate measure of success, he argues, will be clinical: trustworthy tools that translate into earlier, more accurate diagnosis and safer, more personalised care for patients. If CHAIN succeeds, it could offer something Europe has lacked so far, a coherent, continent-scale pathway for moving AI in medicine from promising publications to measurable patient impact, and a model that other fields of medicine, from oncology to neurology, may soon seek to replicate.

Subject of Research: A European initiative to validate and scale artificial intelligence for cardiovascular disease prevention, detection and treatment

Article Title: From promise to patient impact: New European initiative aims to accelerate AI in cardiovascular care

Article References: From promise to patient impact: New European initiative aims to accelerate AI in cardiovascular care. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: artificial intelligence, cardiovascular disease, CHAIN, European Society of Cardiology, EU4Health, European Health Data Space, AI validation, federated data, clinical decision support, health data infrastructure, AI passports, digital health

A new commentary published in The Lancet Regional Health – Europe argues that this machinery is in trouble. Written by Gijs Geleijnse of the Netherlands Comprehensive Cancer Organisation and colleagues from cancer registries and research institutions across the continent, the piece lays out a stark diagnosis: despite decades of investment in healthcare digitalisation and the ongoing preparation of the European Health Data Space, the infrastructure underpinning Europe’s cancer registries is frail. Coverage of the continent remains suboptimal, the timeliness of data publication varies widely from country to country, and registries themselves repeatedly cite resource limitations as the main barrier to investing in innovation. The result is a system that cannot reliably answer even basic questions about the state of cancer in Europe today.

The stakes are rising fast. Through the European Cancer Information System, known as ECIS, the registries of the European Network of Cancer Registries reveal cancer inequalities within and between European geographies, showing where progress is being made and where attention is urgently required. But the financial context is shifting beneath them. Cancer spending in Europe is expected to rise by 59 percent by 2050, according to an analytical report from the OECD and the European Commission. Registries are uniquely positioned to guide how that money is spent—supporting the effective allocation of resources and the implementation and evaluation of cancer prevention, early detection and quality of care—yet only if the data they deliver are complete, comparable and current.

One of the most striking asymmetries highlighted in the commentary is regulatory. Many European countries have national legislation on cancer registration, but there is no European regulation governing PBCR-based statistics. That stands in sharp contrast to mortality statistics, which are governed by explicit EU regulation and delivered by national statistics bureaus and Eurostat, ensuring timely and comparable collection of cause-of-death data across the Union. In other words, Europe legally guarantees that it knows how many people die of cancer and where, but not that it knows how many are diagnosed, how they are treated, or whether they survive. For a continent that has made cancer control a flagship policy priority, the gap is difficult to justify.

The technical picture is equally uneven. Europe’s 192 population-based cancer registries follow the registration guidelines issued by the European Commission’s Joint Research Centre together with the ENCR, but their capacity to collect timely, high-quality data varies enormously. Some registries struggle to record basic clinical elements such as stage at diagnosis and the treatments patients actually received—variables that are indispensable for measuring early detection programmes and the quality of care. A survey of registries published in the International Journal of Cancer in 2025 documented this global capacity gap, and recent work mapping European registries has shown that coverage, data availability and the ability to generate real-world evidence differ substantially across the continent.

The timing of the warning matters. The Joint Action CancerWatch, running from 2025 to 2028 with the participation of 92 organisations from 29 countries, aims specifically to improve the timeliness and quality of the registry data feeding into ECIS. The project exists precisely because geographic coverage is incomplete and timely indicators are limited on the platform. Meanwhile, the European Court of Auditors has called for a monitoring framework for the European Commission’s Beating Cancer Plan, noting in a 2026 special report that the wide-ranging plan faces an uncertain future. ECIS was established to monitor the cancer burden in Europe, but the current limitations in registry data infrastructure undermine its ability to fulfil that role. A monitoring plan without a functioning measurement system, the authors imply, is a promise without a receipt.

To close the gap, the commentary sets out a layered set of policy options. At EU level, the authors call for formal recognition of population-based cancer registries as core components of public health systems, an endorsement that would echo the Council Recommendation on strengthening prevention through early detection, which gave EU cancer screening programmes a firm regulatory footing. The European Commission, they argue, should publish explicit criteria for the data quality and timeliness required for registry data on ECIS, so that the quality and progress of cancer registration in member states can be monitored and managed transparently. Under the European Health Data Space Regulation, they further propose a data usage fee for registries that prioritise delivering data and statistics to ECIS—turning registries from passive data suppliers into recognised, resourced participants in the European data economy.

The integration agenda goes further. Registries, the authors contend, should be built into cancer screening programmes and comprehensive cancer centres as an integral element rather than an afterthought, and future EU project proposals on these topics should require the involvement and adequate resourcing of registries for planning, monitoring and evaluation. At member state level, each country should designate an organisation responsible for delivering national registry data to ECIS, acting as the link between EU bodies and regional registries and embedded in the design and monitoring of the national Cancer Mission Hubs. Sustainable funding is only part of the answer: national innovation funds earmarked for artificial intelligence and digital sovereignty should, the authors argue, also support innovation within registries, which are precisely the kind of high-value, privacy-preserving data infrastructure those funds are meant to cultivate.

At the registry level itself, the recommendations are more sober but no less important. Registries should obtain a formal mandate from their governments as a core component of public health and cancer control, giving them the legal standing to negotiate data access and funding. They should also allocate resources to increase the efficiency of data collection and publication—modernising the often manual, fragmented workflows that delay the arrival of statistics by years. The technical direction of travel is clear: automated extraction from electronic health records, standardised coding, and harmonised quality assurance could shorten the lag between diagnosis and data, provided the underlying legal and financial foundations are secure.

The commentary closes with a sentence that doubles as its thesis: we need to count every cancer patient because every patient counts. Timely, rich and high-quality population-based cancer data, the authors argue, are essential for robust monitoring and for evidence-informed European, national and local cancer policies. As Europe prepares to spend hundreds of billions more on cancer care over the coming decades, the unglamorous work of counting cases, staging tumours and tracking survival may prove to be the highest-yield investment of all. The alternative—policy made in the dark—would be far more expensive, and far less equitable, than the registries themselves.

Subject of Research: Strengthening population-based cancer registries in Europe to improve cancer control and monitoring

Article Title: Every cancer patient counts: strengthening European population-based cancer registries to improve cancer control

Article References: Geleijnse, G., Backes, C., Chirlaque, M. D., Sloep, M., Rodon Navarro, E., Šekerija, M., van Eycken, L., & Ursin, G. (2026). Every cancer patient counts: strengthening European population-based cancer registries to improve cancer control. The Lancet Regional Health – Europe, 70, Article 101855. https://doi.org/10.1016/j.lanepe.2026.101855

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101855

Keywords: cancer registries, population-based cancer registries, European Cancer Information System, ECIS, European Network of Cancer Registries, cancer surveillance, Beating Cancer Plan, European Health Data Space, cancer incidence, cancer survival, health policy, Europe